UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000007576
Receipt No. R000008931
Scientific Title Investigation of Dual-HER2 Blockage Therapy in HER2-Positive Breast Cancer (exploratory randomized P-II)( JBCRG-16 NeoLath)
Date of disclosure of the study information 2012/03/26
Last modified on 2019/09/05 14:19:47

No. Disposal Last modified on Item of update
1 Insert 2012/03/26 19:23:46
2 Update 2012/03/26 19:34:19 Date of disclosure of the study information
3 Update 2012/09/12 15:53:12 Recruitment status
4 Update 2012/10/03 00:24:22 Institutions
5 Update 2012/10/03 00:27:16 Anticipated trial start date
6 Update 2012/11/01 12:00:22 Institutions
7 Update 2013/04/28 21:23:31 Division name
8 Update 2013/06/17 16:44:28 Acronym
Acronym
9 Update 2013/10/28 09:23:06 Email
10 Update 2013/10/28 09:24:24 Recruitment status
11 Update 2013/10/28 09:50:28 Key exclusion criteria
12 Update 2014/09/26 10:45:16 Address
Address
TEL
13 Update 2014/10/30 14:05:58 Last follow-up date
14 Update 2015/04/28 10:38:34 Publication of results
Results
Results
15 Update 2015/10/01 14:50:07 Results
Results
16 Update 2016/05/09 09:21:21 Name of primary sponsor
Organization
17 Update 2018/08/23 15:09:34 Recruitment status
Last follow-up date
18 Update 2018/08/23 17:40:21 Public title
Acronym
19 Update 2018/08/24 10:06:21 UMIN ID1
UMIN ID2
20 Update 2019/09/05 14:10:46 1st name of lead principal investigator
Last name of lead principal investigator
1st name of lead principal investigator
Last name of lead principal investigator
Zip code
Address
Address

Last name of contact person

Last name of contact person
Zip code
Address
Address
Organization
Organization
Address
Address
Tel
Email
21 Update 2019/09/05 14:15:43 Number of participants that the trial has enrolled
Results date posted
Results Delayed
Results Delay Reason
Results Delay Reason
22 Update 2019/09/05 14:16:15 Results
23 Update 2019/09/05 14:16:35 Results
24 Update 2019/09/05 14:19:47 Date of IRB
Last follow-up date


Contact us.